Cover Image
市場調查報告書

抑鈣素基因系胜肽 (CGRP):開發中產品分析

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358694
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
抑鈣素基因系胜肽 (CGRP):開發中產品分析 Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 57 Pages
簡介

本報告提供全球各國治療抑鈣素基因系胜肽 (CGRP) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 抑鈣素基因系胜肽 (CGRP)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • CGRP開發治療藥的企業
    • Alder Biopharmaceuticals Inc.
    • BCN Peptides, S.A.
    • Boehringer Ingelheim GmbH
    • Eli Lilly and Company
    • BCN Peptides, S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Noxxon Pharma AG
  • 藥物簡介
    • ALD-403
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • DD-04107
    • galcanezumab
    • NOXL-41
    • olcegepant
    • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain
    • TEV-48125
  • 開發暫停的計劃
  • 開發中斷的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0529TDB

Summary

Global Markets Direct's, 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016', provides in depth analysis on Calcitonin Gene Related Peptide (CGRP) targeted pipeline therapeutics.

The report provides comprehensive information on the Calcitonin Gene Related Peptide (CGRP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
  • The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Calcitonin Gene Related Peptide (CGRP) Overview
  • Therapeutics Development
    • Calcitonin Gene Related Peptide (CGRP) - Products under Development by Stage of Development
    • Calcitonin Gene Related Peptide (CGRP) - Products under Development by Therapy Area
    • Calcitonin Gene Related Peptide (CGRP) - Products under Development by Indication
  • Calcitonin Gene Related Peptide (CGRP) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Calcitonin Gene Related Peptide (CGRP) - Products under Development by Companies
  • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
    • Alder Biopharmaceuticals Inc.
    • Boehringer Ingelheim GmbH
    • Eli Lilly and Company
    • Noxxon Pharma AG
    • Teva Pharmaceutical Industries Ltd.
  • Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
    • ALD-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galcanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXL-41 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olcegepant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TEV-48125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Calcitonin Gene Related Peptide (CGRP) - Dormant Projects
  • Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
  • Calcitonin Gene Related Peptide (CGRP) - Featured News & Press Releases
    • Sep 08, 2016: Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention
    • Sep 06, 2016: Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer
    • Jul 25, 2016: Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine
    • Jun 09, 2016: Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society
    • Jun 08, 2016: New drug to prevent migraine may start working in days
    • Jun 02, 2016: Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention
    • May 25, 2016: Alder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention
    • Apr 12, 2016: Teva to Present Data on TEV-48125 at 68th AAN Annual Meeting
    • Mar 28, 2016: Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine
    • Feb 09, 2016: Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization
    • Oct 13, 2015: Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine
    • Sep 30, 2015: Important New Data from Teva's TEV-48125 Phase 2B Migraine Program Published in Lancet Neurology in Back-to-Back Articles
    • Jun 18, 2015: Teva to Present New Findings at the American Headache Society Meeting - Analysis of Migraine Phase IIb Studies Provides Novel Insights into TEV-48125 Efficacy and Safety in Both Episodic & Chronic Migraine
    • Jun 17, 2015: Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study
    • May 15, 2015: Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of the International Headache Society
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Alder Biopharmaceuticals Inc., H2 2016
  • Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by Noxxon Pharma AG, H2 2016
  • Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top